No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Primary ADT ineffective for most men with early stage prostate cancer

Data from a large, retrospective study, reported in the Journal of Clinical Oncology, suggest something that many expert clinicians and patients have long suspected … that early use of androgen deprivation therapy (ADT) alone is not an effective treatment for most men with early stage prostate cancer. … READ MORE …

Debulking the primary tumor in men diagnosed with metastatic prostate cancer

There has long been an unanswered question about the value of “debulking” of the primary tumor in men who are initially diagnosed with advanced forms of prostate cancer — i.e., surgical removal of the prostate or some form of definitive radiation therapy of the primary tumor. … READ MORE …

A rare case of angiosarcoma of the prostate

A recent case report by Humphrey in the Journal of Urology offers information about a 67-year-old patient found to have a form of prostate cancer known as angiosarcoma of the prostate. … READ MORE …

Relapse-free survival of non-metastatic patients treated with primary androgen deprivation

Many patients with no specific evidence of metastatic disease now receive primary androgen deprivation therapy (PADT) much earlier than was the case before the availability of the PSA test. This includes patients who get hormone therapy for a rising PSA after other forms of first-line therapy and patients who receive hormone therapy as their first-line treatment. … READ MORE …

Prostate cancer news reports: Wednesday, May 27, 2009

Today’s news reports cover such items as:

  • Identification of prostate cancer cells in urine
  • Prognosis after radiation therapy
  • The effect of bisphenol A on prostate cancer therapy
  • The appropriateness of primary androgen deprivation for localized prostate cancer
  • Data from clinical trials of Phase II clinical trial of docetaxel + samarium-153 lexidronam and cyclophosphamide + dexamethasone in late stage disease … READ MORE …

Get every new post delivered to your Inbox.

Join 1,186 other followers